28 Nov, 2023 Investment community gives the UK a vote of confidence By Dean Outten Yesterday, the government announced that the UK has secured commitment from the world’s leading investors of nearly £30bn. The...
09 Aug, 2023 All at CE? "Indefinite" delay to UKCA requirements in certain sectors By Gustaf Duhs The UK government has had significant issues with the implementation the UK’s post-Brexit products safety conformity mark, the UKCA mark,...
03 May, 2023 Proposed overhaul of clinical research delivery in the UK By Elizabeth Butler During Covid-19, UK clinical research was very much at the front and centre of the global effort to find a vaccine. As we started to...
10 Jun, 2022 No protected costs position for the CMA By Gustaf Duhs On 25 May 2022, the Supreme Court (UKSC) overturned the Court of Appeal’s costs ruling in the Pfizer/Flynn case regarding excessive...
13 Apr, 2022 Definition of excessive pricing in pharma cases re-tweaked? By Gustaf Duhs The CMA’s full text decision in the long-running Hydrocortisone case, originally initiated in 2016 and in which the CMA imposed record...